- Nov 24, 2017
With amendments rendering the ‘poison pill’ effectively inert, private placements have become the de facto M&A defensive tactic. But there are limits to their usefulness.
- Mar 21, 2017
Fixed-fee long-form fairness opinion and report from independent transaction committee must be “minimum standard” in plans of arrangement, says judge
- Aug 02, 2016
The recent refusal of Canadian securities commissions to cease-trade a private placement may indicate that regulators’ approach to defensive tactics under the country’s new hostile takeover bid ...
- Feb 10, 2016
Its shares riding high, Concordia Healthcare was ready to snag UK-based pharma-corp Amdipharm Mercury last September. Then, two weeks after announcement, the deal faced headwinds as The New York ...
- Oct 14, 2015
When COS adopted a second poison pill that would require Suncor to double its 60-day minimum bid period or seek an order terminating the pill, it brought into focus the Canadian Securities ...